X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
index medicus (25) 25
female (19) 19
cancer (18) 18
oncology (18) 18
male (14) 14
mutation (14) 14
neoplasms - genetics (14) 14
middle aged (13) 13
high-throughput nucleotide sequencing (10) 10
therapy (10) 10
cell lung-cancer (9) 9
mutations (9) 9
molecular targeted therapy (8) 8
retrospective studies (8) 8
biomarkers, tumor - genetics (7) 7
cell biology (7) 7
clinical trials (7) 7
neoplasms - pathology (7) 7
precision medicine (7) 7
tumors (7) 7
antineoplastic agents - therapeutic use (6) 6
breast-cancer (6) 6
patients (6) 6
prognosis (6) 6
solid tumors (6) 6
clinical-trials (5) 5
disease-free survival (5) 5
expression (5) 5
genomics (5) 5
high-throughput nucleotide sequencing - methods (5) 5
neoplasms - drug therapy (5) 5
next-generation sequencing (5) 5
personalized medicine (5) 5
tumor suppressor protein p53 - genetics (5) 5
adult (4) 4
aged (4) 4
alterations (4) 4
antineoplastic agents - pharmacology (4) 4
article (4) 4
biopsy (4) 4
blood (4) 4
breast cancer (4) 4
chemotherapy (4) 4
chronic myelogenous leukemia (4) 4
deoxyribonucleic acid--dna (4) 4
gene amplification (4) 4
genetic aspects (4) 4
genomics - methods (4) 4
melanoma (4) 4
multivariate analysis (4) 4
neoplasms - metabolism (4) 4
neoplasms - mortality (4) 4
p53 protein (4) 4
research (4) 4
acquired-resistance (3) 3
actionable mutations (3) 3
aged, 80 and over (3) 3
amplification (3) 3
analysis (3) 3
biomarkers, tumor (3) 3
biomarkers, tumor - blood (3) 3
biomarkers, tumor - metabolism (3) 3
breast neoplasms - drug therapy (3) 3
breast neoplasms - genetics (3) 3
carcinoma (3) 3
cell-free dna (3) 3
colorectal-cancer (3) 3
ctdna (3) 3
dna sequencing (3) 3
dna, neoplasm - genetics (3) 3
drug approval (3) 3
gene expression regulation, neoplastic (3) 3
genetic predisposition to disease (3) 3
k-ras protein (3) 3
kaplan-meier estimate (3) 3
liquid biopsies (3) 3
liquid biopsy (3) 3
medicine (3) 3
neoplasms (3) 3
neoplasms - classification (3) 3
neoplasms - diagnosis (3) 3
pancreatic cancer (3) 3
pathway (3) 3
personalized therapy (3) 3
phase-ii (3) 3
phenotype (3) 3
phosphatidylinositol 3-kinases - genetics (3) 3
pi3k (3) 3
precision medicine - methods (3) 3
receptor, epidermal growth factor - genetics (3) 3
report (3) 3
research paper (3) 3
risk factors (3) 3
survival (3) 3
time factors (3) 3
treatment outcome (3) 3
tumor suppressor protein p53 - metabolism (3) 3
university-of-california (3) 3
aberration (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5101 - 5111
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 32, pp. 3817 - 3825
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2012, Volume 7, Issue 8, p. e44146
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via... 
BREAST-CANCER | SIGNALING PATHWAYS | CANCER CELLS | ONCOGENIC RAS | DUCTAL ADENOCARCINOMA | VASCULATURE | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | KINASE | GROWTH | ANTITUMOR-ACTIVITY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Gene Knockdown Techniques | Mitogen-Activated Protein Kinase Kinases - metabolism | HEK293 Cells | Female | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Pancreatic Neoplasms - pathology | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Pancreatic Neoplasms - enzymology | Pancreatic Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Mutation - genetics | Sulfonamides - pharmacology | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Models, Biological | Cell Line, Tumor | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Ras genes | Gene mutations | Pancreatic cancer | Physiological aspects | Genetic aspects | Research | Risk factors | Drugs | Biomedical research | Disease | Clinical trials | Oncology | Drug delivery | Kinases | Cancer therapies | K-Ras protein | Signal transduction | Pathways | Cell cycle | Xenografts | Tumorigenesis | Inhibition | Medical research | MAP kinase | Data processing | Breast cancer | Maintenance | 1-Phosphatidylinositol 3-kinase | Signaling | Models | In vivo methods and tests | Mutation | Tumors | Cancer
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2014, Volume 124, Issue 10, pp. 1637 - 1644
Key Points Lenalidomide inhibits CLL proliferation in a cereblon/p21-dependent manner. Treatment with lenalidomide induces p21 in CLL independent of p53. 
Lymphoid Neoplasia
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2017, Volume 83, p. 80
Background: Topoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein... 
Enzymes | Therapeutic applications | DNA topoisomerase | Gene expression | Drug development | Patients | ErbB-2 protein | Esophagus | Amplification | Chemotherapy | Gene amplification | Anthracycline | Pancreatic cancer | Gallbladder | Solid tumors | Tumors | Cancer
Journal Article